Global Furmonertinib Mesylate Market Strategic Research Report

Scope of the Report

The global Furmonertinib Mesylate market size is predicted to grow from US$ 923 million in 2025 to US$ 1,912 million in 2032; it is expected to grow at a CAGR of 12.3% from 2026 to 2032.

In 2025, global Furmonertinib Mesylate Tablets production reached approximately 380,000 units.Furmonertinib Mesylate is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily used for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations or the T790M resistance mutation. It works by selectively and irreversibly inhibiting the kinase activity of mutant EGFR, thereby blocking tumor cell proliferation and survival signaling pathways and suppressing tumor growth. Furmonertinib mesylate is characterized by high selectivity for mutant EGFR, good central nervous system penetration, and a relatively manageable safety profile, making it clinically valuable in the treatment of advanced non-small cell lung cancer.

Furmonertinib Mesylate, as a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), operates in a rapidly developing and highly competitive segment of the non-small cell lung cancer (NSCLC) targeted therapy market, particularly demonstrating strong competitiveness in patients with EGFR mutations and T790M resistance mutations. With the large population of lung cancer patients and the continuous improvement in the penetration of genetic testing, the demand for precision medicine is steadily increasing, providing a solid market foundation for this class of drugs.

From a competitive landscape perspective, imported originator drugs represented by Osimertinib have long dominated the market. However, furmonertinib mesylate, leveraging its domestic R&D advantages, price competitiveness, and potential efficacy in patients with central nervous system metastases, is gradually gaining market share in China.

On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although healthcare cost-control measures and volume-based procurement policies continue to exert pressure on pricing. From a competitive standpoint, multiple third-generation EGFR-TKIs and next-generation targeted therapies from both domestic and international companies are continuously entering the market. In addition, the development of immunotherapy combination regimens is further intensifying competition. Therefore, the future market performance of furmonertinib mesylate will depend on its penetration in first-line treatment, expansion of indications (such as adjuvant therapy or additional mutation subtypes), and the accumulation of real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and pricing.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Furmonertinib Mesylate market?

What factors are driving Furmonertinib Mesylate market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Furmonertinib Mesylate market opportunities vary by end market size?

How does Furmonertinib Mesylate break out by Type, by Application?

This report presents a comprehensive overview of the global Furmonertinib Mesylate market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 40 mg
• 80 mg

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• Non-small Cell Lung Cancer (NSCLC) Treatment
• Patients With Central Nervous System Metastases
• First-line and Later-line Targeted Therapy
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Furmonertinib Mesylate market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Non-small Cell Lung Cancer (NSCLC) Treatment, Patients With Central Nervous System Metastases, First-line and Later-line Targeted Therapy evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact